RAISING
Capital to advance our lead program into Phase 2
Restoring cellular energy in diseases that starve the heart
ViCardia Therapeutics is building a first-in-class precision delivery platform designed to reverse mitochondrial metabolic dysfunction — the shared root cause across a range of chronic and rare diseases.
Team & advisors trained and practicing at
Johns Hopkins • Harvard Medical School • UCSF • Washington University • Boston Consulting Group
The Smart Vector Platform
A modular, non-viral delivery architecture engineered to direct bioenergetic therapies to tissue under metabolic stress — supporting a pipeline of programs from one core platform rather than a single molecule.
Tissue-directed delivery
Modular payload design
Non-viral
Multi-indication
• Why it matters
One platform, four lead indications
Mitochondrial dysfunction underlies conditions across cardiology, rare disease, and even human spaceflight. ViCardia's platform is designed to address the shared biology rather than treat each disease in isolation.
Combined U.S. serviceable opportunity >$14B
Pipeline
Four lead indications, one root cause
Each program targets bioenergetic recovery in a distinct patient population — from the hospital, to rare genetic disease, to long-duration spaceflight.
Indication 01
Acute Decompensated Heart Failure
Bioenergetic rescue therapy for patients hospitalized with acute heart failure.
U.S. SOM
$1B–$3B
Heart Failure with Preserved Ejection Fraction
Targeting the underlying dysfunction in a disease affecting more than 3M Americans with no approved therapy for it.
U.S. SOM
$6B–$8B
Indication 03
Friedreich's Ataxia
U.S. SOM
$0.5B–$1B
Indication 04
Cardiac Muscle Atrophy in Microgravity
Supporting astronaut cardiac health during long-duration spaceflight missions.
Emerging SOM
$1B–$2B (est.)
>$14B Combined U.S. serviceable opportunity across ViCardia’s four lead indications
Where We Are
Advancing toward Phase 2
Our scientific advisory board — including former Heart Failure Society of America presidents — has directly shaped our Phase 2 study design and clinical protocol.
Preclinical validation
Platform mechanism and lead candidate validated across preclinical models.
IND-enabling studies
Advancing toward regulatory filing for our lead cardiology indication.
Phase 2 initiation
Clinical protocol shaped by our SAB, including planned principal investigators.
Pipeline expansion
Extending the platform into additional lead indications.
Key Leadership
Built by operators who've done this before
ViCardia is led by a management team, board, and scientific advisory board with backgrounds spanning clinical cardiology, drug development, and company building.
Michael Kokesh, J.D.
Co-Founder, President & CEO
Co-founder of ViCardia Therapeutics. Four-time founder/executive of VC-backed medtech and healthcare companies, twice serving as CEO — including one completed IPO. Former CEO of the Ischemia Research and Education Foundation, a cardiovascular research institute at UCSF.
Education University of Colorado Boulder · UC Law San Francisco
Track record 4x VC-backed company builder
“MitoForge is the key to treating mitochondrial metabolic dysfunction across chronic and rare disease.”
John Teerlink, MD
Co-Chair, Scientific Advisory Board · Professor of Medicine, UCSF · Former President, Heart Failure Society of America
Douglas L. Mann, MD
Javed Butler, MD, MPH, MBA
Scientific Advisory Board · President, Baylor Scott & White Research Institute
Let's talk
ViCardia is currently raising capital to advance our lead program into Phase 2 and expand across our pipeline. Reach out and our team will follow up directly.
mkokesh@vicardia.com
Phone
###-###-####
Office
530 Bush Street, Suite 802, San Francisco, CA 94108